New President at IPHA

Aidan Lynch, Vice President and General Manager of GSK (Ireland) Limited, has been elected as President of the Irish Pharmaceutical Healthcare Association (IPHA).

Read more

New Report Backs Biopharma Innovation as Enabler for New Treatments, Jobs and Investments, says IPHA

Protecting Ireland’s innovation policy environment is key to developing new medicines for patients, and to attracting fresh investments in pharmaceutical manufacturing and research, according to a report published today [Friday] by EY-DKM, the economic advisory consultants. 

Read more

NEW IPHA DATA SHOWS IRISH PATIENTS DENIED ACCESS TO VITAL CANCER MEDICINES

Irish patients are among the last in western Europe to have access to vital cancer medicines, placing at risk the Government’s target to put Ireland in the top quartile of European countries for cancer survival within the next decade.

 

Read more

Biopharma Industry’s Latest Price Drops Save €15m on Government’s Medicines Bill, says IPHA

Ireland’s research-based pharmaceutical industry is set to save the Government €15 million on medicines by introducing price reductions today [Sunday] for more than 750 packs of innovative medicines

Read more

IPHA Urges Progress on Access to Medicines as Ireland Signs Up to BeNeLuxA

As Ireland signed up today [Friday] to the BeNeLuxA Initiative on pricing and supply of innovative medicines, the Irish Pharmaceutical Healthcare Association (IPHA) has said the focus of policymakers and industry must remain on fixing a slow and inefficient medicines approvals process for Irish patients

Read more

Focus must remain on biopharma innovation as European Commission proposes new IP laws, says IPHA

The Irish Pharmaceutical Healthcare Association (IPHA), which represents the research-based pharmaceutical industry in Ireland, has said a continued focus on innovation is key to unlocking the potential of new medicines to improve healthcare outcomes and attract investments in the future.

Read more

Medicines Availability Bulletin Ireland and Europe

NEW IPHA RESEARCH SHOWS THAT IRELAND CONTINUES TO LAG EUROPE

  • Ireland lags western European countries in availability of new medicines
  • Nine medicines in the Irish reimbursement system are already available in 12 western European countries, on average.
  • Cancer and cardiovascular care the main therapy areas affected
  • Ireland 18th of 26 European countries in availability of new medicines:  latest EFPIA research

Read more

Also in this section